Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
I’ve taken and written about a host of evidence-based, non-conventional multiple myeloma therapies. Silymarin aka Milk Thistle is yet another of these MM therapies. The additional benefit of milk thistle however, is its ability to promote liver health. And those of us who have endured multiple myeloma chemotherapies, both induction as well as stem cell transplants (ASCT), have probably damaged our livers. MM chemo is highly toxic.
Let’s face it. The liver is one of the, if not the most important organs. Coming from someone who suffers from chemotherapy-induced cardiomyopathy, that’s saying a lot.
Naming your most important organ is like asking a parent to choose a favorite child. All or our organs have strengths and weaknesses. However, everyone can agree that the liver health is critical to human life. Further, anyone who has undergone chemotherapy knows that his/her liver has been hammered. Healing liver damage is also critical to human life.
In addition to citing the benefits to your liver of milk thistle supplementation, the second article linked below cites vitamin D to reduce the risk of liver cancer. In short, supplementation can make for a healthier liver.
I supplement with and recommend Life Extension European Milk Thistle-Advanced Phospholipid Delivery Softgels–
Have you been diagnosed with multiple myeloma? What stage? What symptoms? I am both a MM survivor and MM coach. Please scroll down the page, post a question or comment and I will reply ASAP.
Multiple myelomas (MM), a monoclonal tumor of plasma cells, is the second most frequent and age-adjusted hematological malignancy. The incidence of MM is 100,000 per year in the USA and Europe . MM cells were characterized by extensive somatic hypermutation of immunoglobulin genes, high bone marrow dependence, and absence of IgM expression. So far, the treatments of MM are primarily chemotherapies in conjunction with proteasome inhibitors (PIs), bone marrow (BM) transplantation, and antiresorptive agents such as bisphosphonates corticosteroids. Silibinin has, however, been demonstrated to exert anti-multiple myeloma efficacy. Silibinin inhibition of cellular proliferation and increased apoptosis via repression of PI3K/Akt-(mammalian target of rapamycin) mTOR signaling have been recently reported to occur in U266 MM cells …”
“The aim of the present study was to investigate whether silybin suppresses the proliferation and induces apoptosis of multiple myeloma (MM) cells and to elucidate its molecular targets.
The results revealed that silybin restrained the proliferation and enhanced the apoptosis of U266 cells. Furthermore, silybin inhibited the protein expression of PI3K, p‑Akt and p‑mTOR in U266 cells. Of note, inhibition of PI3K facilitated silybin‑mediated reduction of mTOR activation, cell proliferation and induction of apoptosis in U266 cells, while activation of PI3K attenuated the effects of silybin. In conclusion, silybin suppressed cell proliferation and promoted apoptosis of U266 cells via PI3K/Akt-mTOR signaling pathways…”